SHH and medulloblastoma: Not only that, but also the crosstalk between SHH and other oncogenic pathways that are commonly overactivated in medulloblastoma, such as PI3K/mTOR and RAS/REF/MEK, can play a significant role in evading SMO inhibition [6].